VERTEX PHARMACEUTICALS INC / MA Net Cash Provided by (Used in) Investing Activities, Continuing Operations
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $104.47 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-02-23
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-06-30 was $278.44M, a 209.79% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-03-31 was $214.04M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) investing activities, continuing operations for the quarter ending 2014-12-31 was -$18.01M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) investing activities, continuing operations for the quarter ending 2014-09-30 was $30.55M, a 38.34% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $104.47M, a 61.14% decline from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $268.86M, a 227.84% increase from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $82.01M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$112.56M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $104.47M 10-K · filed 2017-02-23 | ||||
| 2015-12-31 | $268.86M 10-K · filed 2017-02-23 | ||||
| 2015-06-30 | $278.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $492.48M 10-Q · filed 2015-08-04 | $474.47M derived: sum of 3 quarters · filed 2017-02-23 | $505.01M derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-03-31 | $214.04M 10-Q · filed 2015-05-04 | $196.03M derived: sum of 2 quarters · filed 2017-02-23 | $226.57M derived: sum of 3 quarters · filed 2017-02-23 | $316.45M derived: sum of 4 quarters · filed 2017-02-23 | |
| 2014-12-31 | -$18.01M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $12.53M derived: sum of 2 quarters · filed 2017-02-23 | $102.42M derived: sum of 3 quarters · filed 2017-02-23 | $82.01M 10-K · filed 2017-02-23 | $73.96M 10-K · filed 2015-02-13 |
| 2014-09-30 | $30.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $120.43M derived: sum of 2 quarters · filed 2015-08-04 | $100.02M 10-Q · filed 2014-11-06 | -$19.79M derived: sum of 4 quarters · filed 2016-02-16 | |
| 2014-06-30 | $89.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $69.47M 10-Q · filed 2015-08-04 | -$50.34M derived: sum of 3 quarters · filed 2016-02-16 | -$799.00K derived: sum of 4 quarters · filed 2016-02-16 | |
| 2014-03-31 | -$20.41M 10-Q · filed 2015-05-04 | -$140.22M derived: sum of 2 quarters · filed 2016-02-16 | -$90.68M derived: sum of 3 quarters · filed 2016-02-16 | -$95.37M derived: sum of 4 quarters · filed 2016-02-16 | |
| 2013-12-31 | -$119.81M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | -$70.27M derived: sum of 2 quarters · filed 2016-02-16 | -$74.97M derived: sum of 3 quarters · filed 2016-02-16 | -$112.56M 10-K · filed 2016-02-16 | -$54.13M 10-K · filed 2014-02-11 |
| 2013-09-30 | $49.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $44.84M derived: sum of 2 quarters · filed 2014-11-06 | $7.25M 10-Q · filed 2014-11-06 | $14.40M derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-06-30 | -$4.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$42.29M 10-Q · filed 2014-07-31 | -$35.13M derived: sum of 3 quarters · filed 2015-02-13 | -$166.36M derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-03-31 | -$37.60M 10-Q · filed 2014-05-05 | -$30.44M derived: sum of 2 quarters · filed 2015-02-13 | -$161.67M derived: sum of 3 quarters · filed 2015-02-13 | -$231.71M derived: sum of 4 quarters · filed 2015-02-13 | |
| 2012-12-31 | $7.16M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$124.07M derived: sum of 2 quarters · filed 2015-02-13 | -$194.12M derived: sum of 3 quarters · filed 2015-02-13 | -$425.82M 10-K · filed 2015-02-13 | |
| 2012-09-30 | -$131.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$201.27M derived: sum of 2 quarters · filed 2013-11-07 | -$432.97M 10-Q · filed 2013-11-07 | -$820.75M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-06-30 | -$70.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | -$301.75M 10-Q · filed 2013-08-02 | -$689.52M derived: sum of 3 quarters · filed 2014-02-11 | -$668.08M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-03-31 | -$231.70M 10-Q · filed 2013-05-08 | -$619.48M derived: sum of 2 quarters · filed 2014-02-11 | -$598.03M derived: sum of 3 quarters · filed 2014-02-11 | -$425.24M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2011-12-31 | -$387.78M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$366.33M derived: sum of 2 quarters · filed 2014-02-11 | -$193.54M derived: sum of 3 quarters · filed 2014-02-11 | $212.41M 10-K · filed 2014-02-11 | |
| 2011-09-30 | $21.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $194.24M derived: sum of 2 quarters · filed 2012-11-06 | $600.19M 10-Q · filed 2012-11-06 | $430.49M derived: sum of 4 quarters · filed 2013-03-01 | |
| 2011-06-30 | $172.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $578.74M 10-Q · filed 2012-08-08 | $409.05M derived: sum of 3 quarters · filed 2013-03-01 | ||
| 2011-03-31 | $405.95M 10-Q · filed 2012-05-10 | $236.26M derived: sum of 2 quarters · filed 2013-03-01 | |||
| 2010-12-31 | -$169.69M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $7.30M 10-K · filed 2013-03-01 | |||
| 2010-09-30 | $177.00M 10-Q · filed 2011-11-03 | ||||
| 2009-12-31 | -$508.73M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |